Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (TNGX) reported significant executive leadership changes effective January 8, 2026, as detailed in its Q1 2026 filing. Dr. Barbara Weber, the former President and Chief Executive Officer, retired from her executive role but will continue to serve the company as Executive Chair until December 31, 2026, providing advisory services for a smooth transition. Her departure was explicitly stated not to be a result of any disagreement with the company's operations, policies, or practices, indicating a planned succession. Dr. Weber's compensation as Executive Chair includes an annual base salary of $362,000 and a prorated target cash bonus of 60% of her prior base salary.

Succeeding Dr. Weber, Dr. Malte Peters, a current member of the Board of Directors, was appointed as the new President and Chief Executive Officer. Dr. Peters' compensation package is robust, featuring an annual base salary of $720,000 and a target cash bonus opportunity of 60% of his base salary, prorated for partial service. Furthermore, to align his long-term interests with shareholder value, Dr. Peters was granted an option to purchase 1,650,000 shares of common stock, vesting over approximately four years, and 350,000 restricted stock units (RSUs) vesting in three equal annual installments. His full employment agreement is contingent upon receiving U.S. work authorization.

It is important to note that this specific filing, an Item 2.02 and 5.02 disclosure, primarily focuses on these leadership changes and their associated compensatory arrangements. The document explicitly states that it 'does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025' and therefore, no Q1 2026 financial performance data, such as revenue, earnings, EPS, or forward guidance, is available within this transcript. Consequently, a detailed financial performance breakdown, analysis of strategic initiatives beyond leadership, competitive positioning, or market trends cannot be derived from this document. The company did issue a press release and updated its corporate presentation on January 8, 2026, to announce these changes to investors and analysts.